6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Sign false

פרפל ביוטק בע"מ	2 380
PURPLE BIOTECH LTD
Corporation no: 520031238	12724

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	03/05/2025
	www.isa.gov.il			www.tase.co.il				Reference:	2025-02-030733	Time of broadcast: 22:03 22:03

Immediate Report

Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on

6K: Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups

ea023970304-6k_purpleEDGAR2_Bannerless_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 06/08/2024
Address: Oppenheimer, Science Park 4 , Rehovot 7670104   , Israel Tel: 03-9333121 , 03-9311321 Fax: 03-5097196
E-mail address: ir@purple-biotech.com   Company site: www.kitovpharma.com
Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD,
Name of the Signatory: Masas Ludmer Adi Position of Signatory in the reporting corporation: Company Controller Name of Employer Company:
Address: Menachem Begin Drive 132 , Tel Aviv 6701101 Telephone: 03-9333121 Facsimile: 03-5097196 E-mail: adim@kitovpharma.com 1
Israel